Undisclosed nectin pathway member and additional undisclosed cancer-associated antigens

Undisclosed nectin pathway member and additional undisclosed cancer-associated antigens refers to the target profile of NTX3A13, a multispecific therapeutic antibody developed by Nectin Therapeutics. The nectin pathway consists of a family of immunoglobulin-like cell adhesion molecules, such as Nectin-4 and PVR (CD155), which are frequently overexpressed in various cancers and play significant roles in tumor cell adhesion, migration, and immune evasion by interacting with receptors like TIGIT and DNAM-1 (1, 10). This target profile involves a key, currently proprietary member of this pathway alongside other tumor-associated antigens to enhance the specificity and potency of the therapeutic intervention (10). By binding to multiple antigens simultaneously, drugs targeting this profile aim to disrupt critical signaling networks and overcome the limitations of single-antigen therapies, such as antigen loss or heterogeneous expression (1, 10). This approach is intended to provide a more robust anti-tumor response in both solid and hematological malignancies while minimizing off-target effects through increased precision in tumor cell recognition (10).

Other names

NTX3A13 targetMultispecific nectin pathway targetNectin pathway-associated multispecific antigens

The target is addressed by a multispecific antibody that simultaneously binds to a key member of the nectin pathway and other cancer-associated antigens to selectively target tumor cells, disrupt signaling networks, and prevent immune evasion.